

Robert S Brown Jr

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11339147/robert-s-brown-jr-publications-by-year.pdf>

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

188
papers

13,121
citations

59
h-index

114
g-index

211
ext. papers

15,708
ext. citations

7.8
avg, IF

6.2
L-index

#	Paper	IF	Citations
188	Nirmatrelvir/ritonavir use: Managing clinically significant drug-drug interactions with transplant immunosuppressants.. <i>American Journal of Transplantation</i> , 2022 ,	8.7	6
187	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA-AH).. <i>Liver International</i> , 2022 ,	7.9	1
186	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 2329-2332	11.2	
185	Hepatology Highlights. <i>Hepatology</i> , 2021 , 73, 1245-1247	11.2	
184	Hepatology Highlights. <i>Hepatology</i> , 2021 , 73, 2085-2088	11.2	0
183	Dynamic α Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma. <i>JAMA Surgery</i> , 2021 , 156, 559-567	5.4	2
182	Can Living Donor Liver Transplantation in the United States Reach Its Potential?. <i>Liver Transplantation</i> , 2021 , 27, 1644-1652	4.5	1
181	The Level of Alcohol Consumption in the Prior Year Does Not Impact Clinical Outcomes in Patients With Alcohol-Associated Hepatitis. <i>Liver Transplantation</i> , 2021 , 27, 1382-1391	4.5	0
180	Management of Hepatic Coagulopathy in Bleeding and Nonbleeding Patients: An Evidence-Based Review. <i>Journal of Intensive Care Medicine</i> , 2021 , 36, 524-541	3.3	3
179	SARS-CoV-2 infection increases tacrolimus concentrations in solid-organ transplant recipients. <i>Clinical Transplantation</i> , 2021 , 35, e14193	3.8	3
178	National Trends in Location of Death in Patients With End-Stage Liver Disease. <i>Liver Transplantation</i> , 2021 , 27, 165-176	4.5	3
177	A Review of the Current State of Liver Transplantation Disparities. <i>Liver Transplantation</i> , 2021 , 27, 434-443	4.5	10
176	Hepatology Highlights. <i>Hepatology</i> , 2021 , 73, 1-3	11.2	
175	Hepatology Highlights. <i>Hepatology</i> , 2021 , 73, 475-478	11.2	
174	Reply. <i>Liver Transplantation</i> , 2021 , 27, 606	4.5	
173	The Current Management of Hepatorenal Syndrome-Acute Kidney Injury in the United States and the Potential of Terlipressin. <i>Liver Transplantation</i> , 2021 , 27, 1191-1202	4.5	1
172	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 1-4	11.2	2

171	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 539-542	11.2	
170	Mortality, sepsis, and organ failure in hospitalized patients with cirrhosis vary by type of infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 ,	4	2
169	Hepatology Highlights. <i>Hepatology</i> , 2021 , 74, 1137-1140	11.2	
168	Black Patients Have Unequal Access to Listing for Liver Transplantation in the United States. <i>Hepatology</i> , 2021 , 74, 1523-1532	11.2	7
167	Hepatology Highlights. <i>Hepatology</i> , 2020 , 72, 1893-1896	11.2	
166	Hepatology Highlights. <i>Hepatology</i> , 2020 , 72, 1505-1508	11.2	
165	Role of Terlipressin and Albumin for Hepatorenal Syndrome in Liver Transplantation. <i>Liver Transplantation</i> , 2020 , 26, 1328-1336	4.5	3
164	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 771-773	11.2	
163	Intestinal Virome in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020 , 72, 2182-2196	11.2	29
162	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 405-407	11.2	
161	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 1-3	11.2	1
160	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 1527-1529	11.2	
159	Hepatology Highlights. <i>Hepatology</i> , 2020 , 71, 1143-1145	11.2	
158	COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. <i>American Journal of Transplantation</i> , 2020 , 20, 1800-1808	8.7	474
157	Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. <i>Liver International</i> , 2020 , 40, 1841-1852	7.9	28
156	Development and external validation of a prediction risk model for short-term mortality among hospitalized U.S. COVID-19 patients: A proposal for the COVID-AID risk tool. <i>PLoS ONE</i> , 2020 , 15, e0239536	3.7	22
155	SARS-COV-2 infection (coronavirus disease 2019) for the gastrointestinal consultant. <i>World Journal of Gastroenterology</i> , 2020 , 26, 1546-1553	5.6	37
154	Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. <i>Journal of Hepatology</i> , 2020 , 72, 441-449	13.4	60

153	Patient Perspectives of High-Quality Care on the Liver Transplant Waiting List: A Qualitative Study. <i>Liver Transplantation</i> , 2020 , 26, 238-246	4.5	2
152	The North American Consortium for the Study of End-Stage Liver Disease-Acute-on-Chronic Liver Failure Score Accurately Predicts Survival: An External Validation Using a National Cohort. <i>Liver Transplantation</i> , 2020 , 26, 187-195	4.5	12
151	Hepatology Highlights. <i>Hepatology</i> , 2020 , 72, 791-793	11.2	
150	Multicenter Study to Transplant Hepatitis C-Infected Kidneys (MYTHIC): An Open-Label Study of Combined Glecaprevir and Pibrentasvir to Treat Recipients of Transplanted Kidneys from Deceased Donors with Hepatitis C Virus Infection. <i>Journal of the American Society of Nephrology: JASN</i> , 2020 , 31, 2678-2687	12.7	28
149	Hepatology Highlights. <i>Hepatology</i> , 2020 , 72, 369-370	11.2	
148	Evaluation of Alcohol Taxes as a Public Health Opportunity to Reduce Liver Transplant Listings for Alcohol-Related Liver Disease. <i>Alcoholism: Clinical and Experimental Research</i> , 2020 , 44, 2307-2315	3.7	1
147	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients With Alcoholic Hepatitis. <i>Hepatology</i> , 2020 , 71, 522-538	11.2	71
146	Utilization of Hepatitis C Virus (HCV)-Viremic Organs for HCV Negative Recipients: Is Practice Speeding Past the Evidence?. <i>Hepatology</i> , 2020 , 71, 4-7	11.2	6
145	Opioid epidemic and liver disease. <i>JHEP Reports</i> , 2019 , 1, 240-255	10.3	8
144	Intestinal Fungal Dysbiosis and Systemic Immune Response to Fungi in Patients with Alcoholic Hepatitis. <i>Gastroenterology</i> , 2019 , 156, S-1186	13.3	2
143	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 469-472	11.2	
142	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 2311-2314	11.2	1
141	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 1365-1368	11.2	
140	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 1849-1851	11.2	
139	A Call to Standardize Definitions, Data Collection, and Outcome Assessment to Improve Care in Alcohol-Related Liver Disease. <i>Hepatology</i> , 2019 , 70, 1038-1044	11.2	11
138	Management of Virologic Failure in Patients with Chronic Hepatitis B Treated with Nucleos(t)ide Analogues. <i>Current Hepatology Reports</i> , 2019 , 18, 363-369	1	
137	Treatment Status of Hepatocellular Carcinoma Does Not Influence Rates of Sustained Virologic Response: An HCV-TARGET Analysis. <i>Hepatology Communications</i> , 2019 , 3, 1388-1399	6	5
136	Hepatology Highlights. <i>Hepatology</i> , 2019 , 70, 1497-1499	11.2	1

135	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 927-930	11.2	
134	Hepatology Highlights. <i>Hepatology</i> , 2019 , 70, 1881-1884	11.2	
133	Bacteriophage targeting of gut bacterium attenuates alcoholic liver disease. <i>Nature</i> , 2019 , 575, 505-511	50.4	245
132	Hepatology Highlights. <i>Hepatology</i> , 2019 , 69, 1-4	11.2	1
131	Hepatology Highlights. <i>Hepatology</i> , 2018 , 67, 817-819	11.2	
130	Glecaprevir/Pibrentasvir Treatment in Liver or Kidney Transplant Patients With Hepatitis C Virus Infection. <i>Hepatology</i> , 2018 , 68, 1298-1307	11.2	121
129	Dysregulation of serum bile acids and FGF19 in alcoholic hepatitis. <i>Journal of Hepatology</i> , 2018 , 69, 396-405	40.4	83
128	Hepatology Highlights. <i>Hepatology</i> , 2018 , 67, 1647-1650	11.2	
127	Hepatology Highlights. <i>Hepatology</i> , 2018 , 67, 1195-1197	11.2	
126	Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. <i>Hepatology</i> , 2018 , 67, 1560-1599	11.2	1460
125	Liver atrophy and regeneration in noncirrhotic portal vein thrombosis: Effect of surgical shunts. <i>Liver Transplantation</i> , 2018 , 24, 881-887	4.5	6
124	Early Postoperative Neutrophil Gelatinase-Associated Lipocalin Predicts the Development of Chronic Kidney Disease After Liver Transplantation. <i>Transplantation</i> , 2018 , 102, 809-815	1.8	6
123	Nonviral or Drug-Induced Etiologies of Acute Liver Failure. <i>Clinics in Liver Disease</i> , 2018 , 22, 347-360	4.6	6
122	Ledipasvir/sofosbuvir for treatment of hepatitis C virus in sofosbuvir-experienced, NS5A treatment-naïve patients: Findings from two randomized trials. <i>Liver International</i> , 2018 , 38, 1010-1021	7.9	8
121	Reply. <i>Hepatology</i> , 2018 , 68, 1658-1660	11.2	2
120	Critical Care Management of Gastrointestinal Bleeding and Ascites in Liver Failure. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2018 , 39, 566-577	3.9	1
119	Delayed calcineurin inhibitor introduction and renal outcomes in liver transplant recipients receiving basiliximab induction. <i>Clinical Transplantation</i> , 2018 , 32, e13415	3.8	6
118	Is it Time to Abandon the Milan Criteria?: Results of a Bicoastal US Collaboration to Redefine Hepatocellular Carcinoma Liver Transplantation Selection Policies. <i>Annals of Surgery</i> , 2018 , 268, 690-699	7.8	46

117	American Gastroenterological Association Institute Technical Review on Initial Testing and Management of Acute Liver Disease. <i>Gastroenterology</i> , 2017 , 152, 648-664.e5	13.3	9
116	Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. <i>Hepatology</i> , 2017 , 66, 1090-1101	11.2	127
115	Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story. <i>Annals of Surgery</i> , 2017 , 265, 557-564	7.8	137
114	HCV Antiviral Therapy in Liver Transplant Candidates and Recipients With Renal Insufficiency. <i>Transplantation</i> , 2017 , 101, 924-932	1.8	3
113	Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study. <i>Transplant International</i> , 2017 , 30, 196-208	3	12
112	Selection of Candidates and Timing of Liver Transplantation 2017 , 1053-1064		
111	A Review of Antiviral Use for the Treatment of Chronic Hepatitis B Virus Infection in Pregnant Women. <i>Gastroenterology and Hepatology</i> , 2017 , 13, 154-163	0.7	1
110	Fasting Blood Ammonia Predicts Risk and Frequency of Hepatic Encephalopathy Episodes in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016 , 14, 903-906.e1	6.9	25
109	Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. <i>Hepatology</i> , 2016 , 63, 319-33	11.2	209
108	Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection. <i>Gastroenterology</i> , 2016 , 150, 419-29	13.3	140
107	Postpartum Laboratory Follow-up in Women With Hepatitis B in Massachusetts From 2007 to 2012. <i>Journal of Clinical Gastroenterology</i> , 2016 , 50, e60-4	3	8
106	Daclatasvir combined with sofosbuvir or simeprevir in liver transplant recipients with severe recurrent hepatitis C infection. <i>Liver Transplantation</i> , 2016 , 22, 446-58	4.5	66
105	Reply. <i>Hepatology</i> , 2016 , 64, 1824-1825	11.2	
104	Spontaneous bacterial peritonitis is a risk factor for renal failure requiring dialysis in waitlisted liver transplant candidates. <i>Clinical Transplantation</i> , 2016 , 30, 502-7	3.8	5
103	Interferon-free therapy for genotype 1 hepatitis C in liver transplant recipients: Real-world experience from the hepatitis C therapeutic registry and research network. <i>Liver Transplantation</i> , 2016 , 22, 24-33	4.5	96
102	Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. <i>Hepatology</i> , 2016 , 63, 284-306	11.2	281
101	Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. <i>Hepatology</i> , 2016 , 63, 307-18	11.2	49
100	Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 122-132	18.8	52

99	HCV Council--critical appraisal of data: recommendations for clinical practice in a rapidly evolving therapeutic landscape. <i>Liver International</i> , 2016 , 36, 488-502	7.9	4
98	Current Indications, Contraindications, Delisting Criteria, and Timing For Transplantation 2015 , 94-104		1
97	The impact of an educational program on HCV patient outcomes using boceprevir in community practices (OPTIMAL trial). <i>Therapeutic Advances in Gastroenterology</i> , 2015 , 8, 263-9	4.7	1
96	Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation. <i>Gastroenterology</i> , 2015 , 148, 108-17	13.3	280
95	Reply: To PMID 24954365. <i>Hepatology</i> , 2015 , 61, 1439	11.2	
94	Reply: To PMID 24954365. <i>Hepatology</i> , 2015 , 62, 1328-9	11.2	
93	Hepatitis C genotype influences post-liver transplant outcomes. <i>Transplantation</i> , 2015 , 99, 835-40	1.8	15
92	High post-transplant virological response in hepatitis C virus infected patients treated with pretransplant protease inhibitor-based triple therapy. <i>Liver International</i> , 2015 , 35, 510-7	7.9	11
91	Telaprevir- and Boceprevir-based Triple Therapy for Hepatitis C in Liver Transplant Recipients With Advanced Recurrent Disease: A Multicenter Study. <i>Transplantation</i> , 2015 , 99, 1644-51	1.8	17
90	Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. <i>Gastroenterology</i> , 2015 , 149, 649-59	13.3	622
89	Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. <i>New England Journal of Medicine</i> , 2015 , 373, 2618-28	59.2	558
88	Long-term quality of life after liver donation in the adult to adult living donor liver transplantation cohort study (A2ALL). <i>Journal of Hepatology</i> , 2015 , 62, 346-53	13.4	62
87	Increased risk of colorectal polyps in patients with non-alcoholic fatty liver disease undergoing liver transplant evaluation. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, 459-68	2.8	17
86	Hepatitis C disease severity in living versus deceased donor liver transplant recipients: an extended observation study. <i>Hepatology</i> , 2014 , 59, 1311-9	11.2	16
85	Standing the test of time: outcomes of a decade of prioritizing patients with hepatocellular carcinoma, results of the UNOS natural geographic experiment. <i>Hepatology</i> , 2014 , 60, 1957-62	11.2	90
84	Randomized, double-blind, controlled study of glycerol phenylbutyrate in hepatic encephalopathy. <i>Hepatology</i> , 2014 , 59, 1073-83	11.2	101
83	Steroid use in acute liver failure. <i>Hepatology</i> , 2014 , 59, 612-21	11.2	122
82	Reply: To PMID 23929808. <i>Hepatology</i> , 2014 , 60, 1448	11.2	

81	Predictors of donor follow-up after living donor liver transplantation. <i>Liver Transplantation</i> , 2014 , 20, 967-76	4.5	8
80	A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy. <i>Journal of Hepatology</i> , 2014 , 61, 508-14	13.4	68
79	Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial. <i>Gastroenterology</i> , 2013 , 145, 1035-1044.e5	13.3	42
78	Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. <i>Liver Transplantation</i> , 2013 , 19, 78-88	4.5	62
77	A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation. <i>Hepatology</i> , 2013 , 57, 1752-62	11.2	97
76	Multicenter review of liver transplant for hepatitis B-related liver disease: disparities in gender and ethnicity. <i>Clinical Transplantation</i> , 2013 , 27, 829-37	3.8	7
75	The Hepatitis Aggressiveness Score (HAS): a novel classification system for post-liver transplantation recurrent hepatitis C. <i>American Journal of Surgical Pathology</i> , 2013 , 37, 104-13	6.7	19
74	Hepatitis C viral infection after liver transplantation. <i>Clinical Liver Disease</i> , 2012 , 1, 73-76	2.2	
73	Hepatitis B virus and human immunodeficiency virus drugs in pregnancy: findings from the Antiretroviral Pregnancy Registry. <i>Journal of Hepatology</i> , 2012 , 57, 953-9	13.4	59
72	Risk of advanced fibrosis with grafts from hepatitis C antibody-positive donors: a multicenter cohort study. <i>Liver Transplantation</i> , 2012 , 18, 532-8	4.5	48
71	Basiliximab induction and delayed calcineurin inhibitor initiation in liver transplant recipients with renal insufficiency. <i>Transplantation</i> , 2011 , 91, 1254-60	1.8	23
70	Impact of Hispanic or Asian ethnicity on the treatment outcomes of chronic hepatitis C: results from the WIN-R trial. <i>Journal of Clinical Gastroenterology</i> , 2011 , 45, 720-6	3	14
69	Do Preoperative Inflammatory Markers Impact on Outcome After Liver Transplantation for Hepatocellular Carcinoma?. <i>Annals of Surgery</i> , 2011 , 254, 383-384	7.8	1
68	Laboratory test results after living liver donation in the adult-to-adult living donor liver transplantation cohort study. <i>Liver Transplantation</i> , 2011 , 17, 409-17	4.5	40
67	Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, open-label study. <i>Hepatology</i> , 2011 , 54, 91-100	11.2	155
66	Hepatitis C virus-infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. <i>Hepatology</i> , 2011 , 54, 418-24	11.2	72
65	Liver transplant recipient survival benefit with living donation in the model for endstage liver disease allocation era. <i>Hepatology</i> , 2011 , 54, 1313-21	11.2	100
64	Hepatocellular carcinoma: review of current treatment with a focus on targeted molecular therapies. <i>Therapeutic Advances in Gastroenterology</i> , 2010 , 3, 55-66	4.7	60

63	Thrombocytopenia with abnormal liver function tests. <i>Clinical Gastroenterology and Hepatology</i> , 2010 , 8, 920-3	6.9	
62	Sorafenib: where do we go from here?. <i>Hepatology</i> , 2010 , 52, 360-9	11.2	80
61	Liver Transplantation: Indications, Preoperative Evaluation and Posttransplantation Management 2010 , 1353-1381		1
60	Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 835-42	10.2	170
59	Performance of the hepatic encephalopathy scoring algorithm in a clinical trial of patients with cirrhosis and severe hepatic encephalopathy. <i>American Journal of Gastroenterology</i> , 2009 , 104, 1392-400 ^{0.7}		60
58	Plasma levels of S100A4 in portopulmonary hypertension. <i>Biomarkers</i> , 2009 , 14, 156-60	2.6	7
57	Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. <i>Annals of Surgery</i> , 2009 , 250, 141-51	7.8	284
56	Serotonin transporter polymorphisms in patients with portopulmonary hypertension. <i>Chest</i> , 2009 , 135, 1470-1475	5.3	34
55	The Dilemma of Adult-to-Adult Living Donor Liver Transplantation 2009 , 65-89		
54	Live donors in liver transplantation. <i>Gastroenterology</i> , 2008 , 134, 1802-13	13.3	138
53	Hepatitis C and liver transplantation: enhancing outcomes and should patients be retransplanted. <i>Clinics in Liver Disease</i> , 2008 , 12, 637-59, ix-x	4.6	32
52	Racial disparities in utilization of liver transplantation for hepatocellular carcinoma in the United States, 1998-2002. <i>American Journal of Gastroenterology</i> , 2008 , 103, 120-7	0.7	64
51	Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2992-8	2.2	387
50	Live donor liver transplantation: current status. <i>Current Gastroenterology Reports</i> , 2008 , 10, 36-42	5	7
49	Risk factors and impact of chronic obstructive pulmonary disease in candidates for liver transplantation. <i>Liver Transplantation</i> , 2008 , 14, 1357-65	4.5	22
48	WIN-R revisited: Response to editorial. <i>Hepatology</i> , 2008 , 47, 1427	11.2	
47	Clinical risk factors for portopulmonary hypertension. <i>Hepatology</i> , 2008 , 48, 196-203	11.2	189
46	Improvement in survival associated with adult-to-adult living donor liver transplantation. <i>Gastroenterology</i> , 2007 , 133, 1806-13	13.3	167

45	Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. <i>Hepatology</i> , 2007 , 46, 982-90	11.2	65
44	Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. <i>Hepatology</i> , 2007 , 46, 1853-62	11.2	293
43	Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. <i>Hepatology</i> , 2007 , 46, 971-81	11.2	256
42	Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation. <i>Liver Transplantation</i> , 2007 , 13, 122-9	4.5	103
41	Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy. <i>American Journal of Gastroenterology</i> , 2007 , 102, 880-9	0.7	77
40	Steroids in recurrent hepatitis C following liver transplantation: pitfall or panacea?. <i>Journal of Hepatology</i> , 2007 , 47, 741-3	13.4	5
39	Hepatitis C virus and liver transplantation. <i>Clinics in Liver Disease</i> , 2006 , 10, 919-40	4.6	82
38	Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1. <i>Gastroenterology</i> , 2006 , 131, 470-7	13.3	405
37	Who should treat liver transplant patients? The transplant hepatologist or the gastroenterologist? Part I: the transplant hepatologist. <i>Journal of Hepatology</i> , 2006 , 44, 655-7	13.4	6
36	The Current State of Liver Transplantation. <i>Gastroenterology and Hepatology</i> , 2006 , 2, 244-246	0.7	
35	Post Liver Transplantation Management and Complications 2006 , 961-974		2
34	A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C. <i>American Journal of Gastroenterology</i> , 2005 , 100, 2453-62	0.7	114
33	Role of the Independent Donor Advocacy Team in Ethical Decision Making. <i>Progress in Transplantation</i> , 2005 , 15, 298-302	1.1	11
32	Hepatitis C and liver transplantation. <i>Nature</i> , 2005 , 436, 973-8	50.4	292
31	The survival impact of liver transplantation in the MELD era, and the future for organ allocation and distribution. <i>American Journal of Transplantation</i> , 2005 , 5, 203-4	8.7	80
30	Predictors of candidate maturation among potential living donors. <i>American Journal of Transplantation</i> , 2005 , 5, 2549-54	8.7	12
29	Kidney and Liver Living Donors: A Comparison of Experiences. <i>Progress in Transplantation</i> , 2005 , 15, 185-191		31
28	Current Indications, Contraindications, Delisting Criteria, and Timing for Liver Transplantation 2005 , 95-114		3

27	Liver and intestine transplantation. <i>American Journal of Transplantation</i> , 2004 , 4 Suppl 9, 81-92	8.7	40
26	Impact of adult living donor liver transplantation on waiting time survival in candidates listed for liver transplantation. <i>American Journal of Transplantation</i> , 2004 , 4, 427-31	8.7	47
25	Adult living donor liver transplantation. <i>American Journal of Transplantation</i> , 2004 , 4, 458-65	8.7	53
24	Is the cost of adult living donor liver transplantation higher than deceased donor liver transplantation?. <i>Liver Transplantation</i> , 2004 , 10, 467-8	4.5	9
23	Prospective, randomized, multicenter, controlled trial of a bioartificial liver in treating acute liver failure. <i>Annals of Surgery</i> , 2004 , 239, 660-7; discussion 667-70	7.8	477
22	Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. <i>American Journal of Gastroenterology</i> , 2003 , 98, 1610-5	0.7	133
21	Transjugular intrahepatic portosystemic shunt for refractory ascites: an analysis of the literature on efficacy, morbidity, and mortality. <i>American Journal of Gastroenterology</i> , 2003 , 98, 2521-7	0.7	59
20	A survey of liver transplantation from living adult donors in the United States. <i>New England Journal of Medicine</i> , 2003 , 348, 818-25	59.2	399
19	Clinical and ethnic differences in candidates listed for liver transplantation with and without potential living donors. <i>Liver Transplantation</i> , 2003 , 9, 254-9	4.5	25
18	Increased risk of cholestatic hepatitis C in recipients of grafts from living versus cadaveric liver donors. <i>Liver Transplantation</i> , 2003 , 9, 1028-35	4.5	98
17	Financial impact of adult living donation. <i>Liver Transplantation</i> , 2003 , 9, S12-5	4.5	18
16	Scope of worldwide hepatitis C problem. <i>Liver Transplantation</i> , 2003 , 9, S10-3	4.5	111
15	Ethical issues in living donor liver transplantation. <i>Current Gastroenterology Reports</i> , 2003 , 5, 26-30	5	13
14	Patients with chronic hepatitis C who have normal ALT: A role for interferon-based therapy?. <i>Current Hepatitis Reports</i> , 2003 , 2, 11-16		
13	Analysis of failure in living donor liver transplantation: differential outcomes in children and adults. <i>World Journal of Surgery</i> , 2003 , 27, 356-64	3.3	49
12	Model for end-stage liver disease and Child-Turcotte-Pugh score as predictors of pretransplantation disease severity, posttransplantation outcome, and resource utilization in United Network for Organ Sharing status 2A patients. <i>Liver Transplantation</i> , 2002 , 8, 278-84	4.5	164
11	Predictors of mortality and stenosis after transjugular intrahepatic portosystemic shunt. <i>Liver Transplantation</i> , 2002 , 8, 271-7	4.5	34
10	Prevention of post-transplant cardiovascular disease--report and recommendations of an ad hoc group. <i>American Journal of Transplantation</i> , 2002 , 2, 491-500	8.7	63

9	Endoscopic Treatment of Patients with Portal Hypertension. <i>Gastrointestinal Endoscopy Clinics of North America</i> , 2001 , 11, 1-14	3.3	4
8	Cost-effectiveness analysis of transjugular intrahepatic portosystemic shunt (TIPS) versus endoscopic therapy for the prevention of recurrent esophageal variceal bleeding. <i>Hepatology</i> , 2000 , 31, 358-63	11.2	70
7	Recommendations for the Outpatient Surveillance of Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2000 , 11, S1-S86	12.7	431
6	Predictors of the cost of liver transplantation. <i>Liver Transplantation</i> , 1998 , 4, 170-6		51
5	Payer status, but not race, affects the cost of liver transplantation. <i>Liver Transplantation</i> , 1998 , 4, 370-7		23
4	The impact of surgical complications after liver transplantation on resource utilization. <i>Archives of Surgery</i> , 1997 , 132, 1098-103		45
3	Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation. <i>Transplantation</i> , 1996 , 62, 1788-93	1.8	127
2	HCV and Liver Transplantation. <i>Current Hepatology Reports</i> , 1		1
1	Living-Donor Liver Transplantation 162-175		